Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 379

1.

Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance-non-antibiotic approaches: a systemic review.

Wawrysiuk S, Naber K, Rechberger T, Miotla P.

Arch Gynecol Obstet. 2019 Jul 26. doi: 10.1007/s00404-019-05256-z. [Epub ahead of print] Review.

PMID:
31350663
2.

Prevention of recurrent urinary tract infections: bridging the gap between clinical practice and guidelines in Latin America.

Ortega Martell JA, Naber KG, Milhem Haddad J, Tirán Saucedo J, Domínguez Burgos JA.

Ther Adv Urol. 2019 May 2;11:1756287218824089. doi: 10.1177/1756287218824089. eCollection 2019 Jan-Dec. Review. Erratum in: Ther Adv Urol. 2019 Jul 05;11:1756287219863170.

3.

Risk factors and predisposing conditions for urinary tract infection.

Storme O, Tirán Saucedo J, Garcia-Mora A, Dehesa-Dávila M, Naber KG.

Ther Adv Urol. 2019 May 2;11:1756287218814382. doi: 10.1177/1756287218814382. eCollection 2019 Jan-Dec. Review.

4.

A step further in a vaccine for Escherichia coli.

Wagenlehner FM, Naber KG.

Lancet Infect Dis. 2019 Jun;19(6):565-567. doi: 10.1016/S1473-3099(19)30069-6. Epub 2019 May 9. No abstract available.

PMID:
31079948
5.

Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli.

Loose M, Naber KG, Hu Y, Coates A, Wagenlehner FME.

Int J Antimicrob Agents. 2019 Jul;54(1):55-61. doi: 10.1016/j.ijantimicag.2019.04.011. Epub 2019 Apr 26.

PMID:
31034939
6.

Appropriate empiric antibiotic choices in health care associated urinary tract infections in urology departments in Europe from 2006 to 2015: A Bayesian analytical approach applied in a surveillance study.

Tandogdu Z, Kakariadis ETA, Naber K, Wagenlehner F, Bjerklund Johansen TE.

PLoS One. 2019 Apr 25;14(4):e0214710. doi: 10.1371/journal.pone.0214710. eCollection 2019.

7.

Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women.

Alidjanov JF, Naber KG, Pilatz A, Radzhabov A, Zamuddinov M, Magyar A, Tenke P, Wagenlehner FM.

World J Urol. 2019 Apr 19. doi: 10.1007/s00345-019-02761-3. [Epub ahead of print]

PMID:
31004204
8.

Metagenomics in diagnosis and improved targeted treatment of UTI.

Dixon M, Stefil M, McDonald M, Bjerklund-Johansen TE, Naber K, Wagenlehner F, Mouraviev V.

World J Urol. 2019 Apr 3. doi: 10.1007/s00345-019-02731-9. [Epub ahead of print]

PMID:
30944967
9.

Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis.

Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FME.

Antibiotics (Basel). 2018 Jan 15;7(1). pii: E6. doi: 10.3390/antibiotics7010006.

10.

Multidisciplinary approach to prostatitis.

Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P, Giuberti R, Granatieri CM, Latino MA, Larganà G, Leli C, Maierna G, Marchese V, Massa E, Matteelli A, Montanari E, Morgia G, Naber KG, Papadouli V, Perletti G, Rekleiti N, Russo GI, Sensini A, Stamatiou K, Trinchieri A, Wagenlehner FME.

Arch Ital Urol Androl. 2019 Jan 18;90(4):227-248. doi: 10.4081/aiua.2018.4.227.

11.

Cefiderocol for treatment of complicated urinary tract infections.

Wagenlehner FME, Naber KG.

Lancet Infect Dis. 2019 Jan;19(1):22-23. doi: 10.1016/S1473-3099(18)30722-9. No abstract available.

PMID:
30587289
12.

Novel Antibiotics in the Treatment of Urinary Tract Infections.

Naber KG, Wagenlehner FME.

Eur Urol Focus. 2019 Jan;5(1):10-12. doi: 10.1016/j.euf.2018.11.012. Epub 2018 Dec 13.

PMID:
30555037
13.

Should We Always Use Antibiotics after Urodynamic Studies in High-Risk Patients?

Miotla P, Wawrysiuk S, Naber K, Markut-Miotla E, Skorupski P, Skorupska K, Rechberger T.

Biomed Res Int. 2018 Nov 5;2018:1607425. doi: 10.1155/2018/1607425. eCollection 2018.

14.

Transurethral Resection of the Prostate: are We Following the Guidelines? - Outcomes from the Global Prevalence of Infections in Urology (GPIU) Study.

Köves B, Tenke P, Tandogdu Z, Cai T, Bogenhard F, Wullt B, Naber K, Bartoletti R, Cek M, Kulchavenya E, Perepanova T, Pilatz A, Bonkat G, Erik Bjerklund Johansen T, Wagenlehner F.

J Chemother. 2019 Feb;31(1):15-22. doi: 10.1080/1120009X.2018.1542552. Epub 2018 Dec 3.

PMID:
30508403
15.

Reliability of Symptom-Based Diagnosis of Uncomplicated Cystitis.

Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FM.

Urol Int. 2019;102(1):83-95. doi: 10.1159/000493509. Epub 2018 Nov 12.

PMID:
30419565
17.

Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli.

Loose M, Naber KG, Hu Y, Coates A, Wagenlehner FME.

Int J Antimicrob Agents. 2018 Dec;52(6):783-789. doi: 10.1016/j.ijantimicag.2018.08.010. Epub 2018 Aug 21.

PMID:
30138665
18.

[Urogenital tuberculosis and schistosomiasis (bilharzia) : Urological challenges in displaced persons].

Naber KG, Kulchavenya E, Bichler KH, Wagenlehner FME.

Urologe A. 2018 Oct;57(10):1191-1199. doi: 10.1007/s00120-018-0760-x. Review. German.

PMID:
30135981
19.

Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part II. Patient-Reported Outcome Assessment.

Alidjanov JF, Naber KG, Abdufattaev UA, Pilatz A, Wagenlehner FM.

Antibiotics (Basel). 2018 May 21;7(2). pii: E43. doi: 10.3390/antibiotics7020043.

20.

The role of the Acute Cystitis Symptom Score questionnaire for research and antimicrobial stewardship. Validation of the Hungarian version.

Magyar A, Alidjanov J, Pilatz A, Nagy K, Arthanareeswaran VKA, Póth S, Bécsi A, Wagenlehner FME, Naber KG, Tenke P, Köves B.

Cent European J Urol. 2018;71(1):134-141. doi: 10.5173/ceju.2018.1530. Epub 2017 Jan 22.

21.

The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention.

Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM.

Urol Int. 2018;100(3):271-278. doi: 10.1159/000487645. Epub 2018 Mar 14.

PMID:
29539622
22.

The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients: Part 1.

Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM.

Urol Int. 2018;100(3):263-270. doi: 10.1159/000486138. Epub 2018 Jan 17.

23.

Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.

Wagenlehner F, Nowicki M, Bentley C, Lückermann M, Wohlert S, Fischer C, Vente A, Naber K, Dalhoff A.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02317-17. doi: 10.1128/AAC.02317-17. Print 2018 Apr.

24.

Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU).

Choe HS, Lee SJ, Cho YH, Çek M, Tandoğdu Z, Wagenlehner F, Bjerklund-Johansen TE, Naber K; GPIU Asian Investigators.

J Infect Chemother. 2018 Apr;24(4):278-283. doi: 10.1016/j.jiac.2017.11.013. Epub 2017 Dec 29.

PMID:
29292177
25.

Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis.

Roberts MJ, Scott S, Harris PN, Naber K, Wagenlehner FME, Doi SAR.

World J Urol. 2018 Mar;36(3):323-330. doi: 10.1007/s00345-017-2163-9. Epub 2017 Dec 29. Review.

PMID:
29288398
26.

Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption.

Loose M, Naber KG, Shields P, Reinhart H, Wagenlehner FME.

Int J Antimicrob Agents. 2018 Mar;51(3):422-426. doi: 10.1016/j.ijantimicag.2017.11.004. Epub 2017 Nov 20.

PMID:
29158143
27.

Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiologic eradication: a noncomparative, prospective observational study.

Forstner C, Kwetkat A, Makarewicz O, Hartung A, Pfister W, Fünfstück R, Hummers-Pradier E, Naber KG, Hagel S, Harrison N, Schumacher U, Pletz MW.

Clin Microbiol Infect. 2018 Apr;24(4):434-435. doi: 10.1016/j.cmi.2017.11.007. Epub 2017 Nov 10. No abstract available.

28.

Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT).

Wagenlehner F, Wullt B, Ballarini S, Zingg D, Naber KG.

Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):107-117. doi: 10.1080/14737167.2017.1359543. Epub 2017 Jul 31.

PMID:
28737469
29.

The Global Prevalence of Infections in Urology (GPUI) Study: A Worldwide Surveillance Study in Urology Patients.

Wagenlehner F, Tandogdu Z, Bartoletti R, Cai T, Cek M, Kulchavenya E, Köves B, Naber K, Perepanova T, Tenke P, Wullt B, Bogenhard F, Bjerklund Johansen TE; GPIU Investigators.

Eur Urol Focus. 2016 Oct;2(4):345-347. doi: 10.1016/j.euf.2016.03.004. Epub 2016 Apr 1.

PMID:
28723463
30.

[Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients : Update 2017 of the interdisciplinary AWMF S3 guideline].

Kranz J, Schmidt S, Lebert C, Schneidewind L, Vahlensieck W, Sester U, Fünfstück R, Helbig S, Hofmann W, Hummers E, Kunze M, Kniehl E, Naber K, Mandraka F, Mündner-Hensen B, Schmiemann G, Wagenlehner FME.

Urologe A. 2017 Jun;56(6):746-758. doi: 10.1007/s00120-017-0389-1. Review. German.

PMID:
28455578
31.

[In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany].

Kresken M, Körber-Irrgang B, Naber KG.

Aktuelle Urol. 2017 May;48(3):243-247. doi: 10.1055/s-0043-102153. Epub 2017 Apr 20. German.

PMID:
28427111
32.

Editorial Comment.

Naber KG, Wagenlehner FME.

J Urol. 2017 Jul;198(1):114-115. doi: 10.1016/j.juro.2017.01.110. Epub 2017 Apr 5. No abstract available.

PMID:
28390220
33.

Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis.

Pinart M, Kranz J, Jensen K, Proctor T, Naber K, Kunath F, Wagenlehner F, Schmidt S.

Int J Infect Dis. 2017 May;58:96-109. doi: 10.1016/j.ijid.2017.03.012. Epub 2017 Mar 21. Review.

34.

[Are there alternatives to antimicrobial therapy and prophylaxis of uncomplicated urinary tract infections?]

Naber KG, Alidjanov JF.

Urologiia. 2016 Aug;(3 Suppl 3):37-44. Russian.

PMID:
28247617
35.

A new way to prevent urinary tract infections?

Wagenlehner FME, Naber KG.

Lancet Infect Dis. 2017 May;17(5):467-468. doi: 10.1016/S1473-3099(17)30107-X. Epub 2017 Feb 24. No abstract available.

PMID:
28238602
36.

[New questionnaire for the German validation of the Acute Cystitis Symptom Score].

Alidjanov JF, Pilatz A, Abdufattaev UA, Wiltink J, Weidner W, Naber KG, Wagenlehner F.

Urologe A. 2017 Mar;56(3):364-366. doi: 10.1007/s00120-017-0327-2. German. No abstract available.

PMID:
28150016
37.

Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches.

Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, Wagenlehner FME.

Urology. 2017 Jun;104:11-21. doi: 10.1016/j.urology.2016.12.011. Epub 2016 Dec 19. Review.

PMID:
28007492
38.

The revival of old antibiotics for treatment of uncomplicated urinary tract infections in the era of antibiotic stewardship.

Kranz J, Helbig S, Mandraka F, Schmidt S, Naber KG.

Curr Opin Urol. 2017 Mar;27(2):127-132. doi: 10.1097/MOU.0000000000000365. Review.

PMID:
27875349
39.

The Acute Cystitis Symptom Score for Patient-Reported Outcome Assessment.

Alidjanov JF, Abdufattaev UA, Makhsudov SA, Pilatz A, Akilov FA, Naber KG, Wagenlehner FM.

Urol Int. 2016;97(4):402-409. Epub 2016 Sep 3.

PMID:
27591987
40.

Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative.

Cai T, Gallelli L, Cocci A, Tiscione D, Verze P, Lanciotti M, Vanacore D, Rizzo M, Gacci M, Saleh O, Malossini G, Liguori G, Trombetta C, Rocco D, Palmieri A, Bartoletti R, Carini M, Wagenlehner FM, Naber K, Mirone V, Bjerklund Johansen TE.

World J Urol. 2017 Feb;35(2):221-228. doi: 10.1007/s00345-016-1867-6. Epub 2016 May 31.

PMID:
27246847
41.

[Correction: Bacteriuria after Radical Prostatectomy: Importance of Bacterial Count].

Vahlensieck W, Naber K, Wagenlehner F, Fabry W.

Aktuelle Urol. 2016 May;47(3):e2. doi: 10.1055/s-0043-115674. Epub 2017 Aug 1. German. No abstract available.

PMID:
28763810
42.

Studying ceftazidime-avibactam in selected populations.

Wagenlehner FME, Naber KG.

Lancet Infect Dis. 2016 Jun;16(6):621-623. doi: 10.1016/S1473-3099(16)30025-1. Epub 2016 Apr 20. No abstract available.

PMID:
27107459
43.

[Bacteriuria after Radical Prostatectomy: Importance of Bacterial Count].

Vahlensieck W, Naber K, Wagenlehner F, Fabry W.

Aktuelle Urol. 2016 May;47(3):243-5. doi: 10.1055/s-0042-103198. Epub 2016 Apr 20. German. Erratum in: Aktuelle Urol. 2016 May;47(3):e2.

PMID:
27096940
44.

Letter to the Editor: Diagnostic Criteria in Urological Diseases do not Always Match with Findings by Extended Culture Techniques and Metagenomic Sequencing of 16S rDNA.

Smelov V, Naber K, Bjerklund Johansen TE.

Open Microbiol J. 2016 Feb 29;10:23-6. doi: 10.2174/1874285801610010023. eCollection 2016.

45.

Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects.

Straubinger M, Blenk H, Naber KG, Wagenlehner FM.

Antimicrob Agents Chemother. 2016 May 23;60(6):3309-15. doi: 10.1128/AAC.02425-15. Print 2016 Jun.

46.

The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections.

Wagenlehner F, Tandogdu Z, Bartoletti R, Cai T, Cek M, Kulchavenya E, Köves B, Naber K, Perepanova T, Tenke P, Wullt B, Bogenhard F, Johansen TE.

Pathogens. 2016 Jan 19;5(1). pii: E10. doi: 10.3390/pathogens5010010.

47.

Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013.

Tandoğdu Z, Bartoletti R, Cai T, Çek M, Grabe M, Kulchavenya E, Köves B, Menon V, Naber K, Perepanova T, Tenke P, Wullt B, Johansen TE, Wagenlehner F.

World J Urol. 2016 Aug;34(8):1193-200. doi: 10.1007/s00345-015-1722-1. Epub 2015 Dec 11.

48.

Urosepsis: Overview of the Diagnostic and Treatment Challenges.

Wagenlehner FME, Pilatz A, Weidner W, Naber KG.

Microbiol Spectr. 2015 Oct;3(5). doi: 10.1128/microbiolspec.UTI-0003-2012. Review.

PMID:
26542042
49.

Two dimensions of social anxiety disorder: a pilot study of the Questionnaire for Social Anxiety and Social Competence Deficits for Adolescents.

Fernandez Castelao C, Naber K, Altstädt S, Kröner-Herwig B, Ruhl U.

Child Adolesc Psychiatry Ment Health. 2015 Oct 8;9:47. doi: 10.1186/s13034-015-0079-y. eCollection 2015.

50.

Editorial commentary: treatment of asymptomatic bacteriuria might be harmful.

Wagenlehner FM, Naber KG.

Clin Infect Dis. 2015 Dec 1;61(11):1662-3. doi: 10.1093/cid/civ698. Epub 2015 Aug 12. No abstract available.

Supplemental Content

Support Center